Segment information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Significant Segment Expenses

The following table is a summary of our significant segment expenses:

	Year ended December 31, 2024		Year ended December 31, 2023
Direct research and development expenses:
VTP-1000 Celiac1	$	5,486	$	8,420
VTP-300 HBV	10,474		11,276
VTP-850 Prostate cancer	1,429		2,726
VTP-200 HPV	2,009		4,950
VTP-600 NSCLC2	473		597
VTP-500 MERS3	610		—
Other and earlier stage programs4	3,228		1,787
Total direct research and development expenses	$	23,709	$	29,756
Indirect research and development expenses:
Personnel-related (including share-based compensation)	15,867		12,702
Facility related	1,249		1,339
Other indirect costs	1,411		1,077
Total indirect research and development expenses	18,527		15,118
Total research and development expenses	$	42,236	$	44,874

1 Research and development expenses related to VTP-1100 HPV Cancer were presented together with VTP-1000 Celiac in the prior period comparative, because our SNAP product candidates were both preclinical. Expenses related to VTP-1100 HPV Cancer are now included in "Other and earlier stage programs," because we are deferring the planned IND application for VTP-1100 in HPV cancer and we have initiated the clinical trial for VTP-1000 Celiac.

2 The VTP-600 NSCLC/ESCC Phase 1/2a trial is sponsored by Cancer Research U.K.

3 The development of VTP-500 is funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI).

4 This includes $0.9 million of personnel-related indirect expenses relating to time spent progressing the VTP-500 MERS program, which is funded by CEPI.

Schedule of Long-Lived Assets

The following table summarizes the Company’s long-lived assets, which include the Company’s intangible assets, property and equipment, net and right-of-use assets by geography:

	Year ended December 31, 2024		Year ended December 31, 2023
United States	$	28,907	$	32,805
United Kingdom	4,797		11,705
	$	33,704	$	44,510